HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications.

Abstract
Various classes of antidepressant drugs with distinct pharmacologic actions are differentially effective in the treatment of classic melancholic depression--characterized by pathological hyperarousal and atypical depression--associated with lethargy, hypersomnia, and hyperphagia. All antidepressant agents exert their therapeutic efficacy only after prolonged administration. In situ hybridization histochemistry was used to examine in rats the effects of short-term (2 weeks) and long-term (8 weeks) administration of 3 different classes of activating antidepressant drugs which tend to be preferentially effective in treating atypical depressions, on the expression of central nervous system genes thought to be dysregulated in major depression. Daily administration (5 mg/kg, i.p.) of the selective 5-hydroxytryptophan (5-HT) reuptake inhibitor fluoxetine, the selective alpha 2-adrenergic receptor antagonist idazoxan, and the nonspecific monoamine oxidase A and B inhibitor phenelzine increased tyrosine hydroxylase mRNA levels by 70-150% in the locus coeruleus after 2 weeks of drug and by 71-115% after 8 weeks. The 3 drugs decreased corticotropin-releasing hormone mRNA levels by 30-48% in the paraventricular nucleus of the hypothalamus. The decreases occurred at 8 weeks but not at 2 weeks. No consistent change in steroid hormone receptor mRNA levels was seen in the hippocampus with the 3 drugs, but fluoxetine and idazoxan increased the level of mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) mRNA, respectively, after 8 weeks of drug administration. Proopiomelanocortin (POMC) mRNA levels in the anterior pituitary and plasma adrenocorticotropic-hormone (ACTH) levels were not altered after 2 or 8 weeks of drug treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsL S Brady, P W Gold, M Herkenham, A B Lynn, H J Whitfield Jr
JournalBrain research (Brain Res) Vol. 572 Issue 1-2 Pg. 117-25 (Feb 14 1992) ISSN: 0006-8993 [Print] Netherlands
PMID1351783 (Publication Type: Journal Article)
Chemical References
  • Adrenergic alpha-Antagonists
  • Antidepressive Agents
  • Dioxanes
  • Mineralocorticoids
  • RNA, Messenger
  • Receptors, Glucocorticoid
  • Receptors, Mineralocorticoid
  • Receptors, Steroid
  • Fluoxetine
  • Corticotropin-Releasing Hormone
  • Tyrosine 3-Monooxygenase
  • Phenelzine
  • Idazoxan
Topics
  • Adrenergic alpha-Antagonists (pharmacology)
  • Animals
  • Antidepressive Agents (pharmacology)
  • Corticotropin-Releasing Hormone (genetics)
  • Dioxanes (pharmacology)
  • Fluoxetine (pharmacology)
  • Idazoxan
  • Locus Coeruleus (drug effects, metabolism)
  • Male
  • Mineralocorticoids
  • Paraventricular Hypothalamic Nucleus (drug effects, metabolism)
  • Phenelzine (pharmacology)
  • RNA, Messenger (genetics, metabolism)
  • Rats
  • Rats, Inbred Strains
  • Receptors, Glucocorticoid (genetics)
  • Receptors, Mineralocorticoid
  • Receptors, Steroid (genetics)
  • Tyrosine 3-Monooxygenase (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: